Testicular cancer and Hodgkin's disease: evaluation of semen quality

Gandini, L.; Lombardo, Francesco; Salacone, Paola; Paoli, Donatella; Anselmo, Anna Paola; Culasso, Franco; Dondero, F.; Lenzi, Andrea

doi:10.1093/humrep/deg163

Cited by 68 publications

(51 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data are in agreement with previous studies. 16,17 The lowest baseline sperm concentration was detected in the TNCT group, while the TNRT group showed higher baseline FSH levels when compared to the TNCT group, likely because of the presence of elevated b-hCG levels with FSH (and spermatogenesis) inhibition in some TNCT patients with non-seminomatous germ cell tumors. 18 On the other hand, baseline inhibin B levels were higher in LDCT and LDRT groups than in TNCT and TNRT groups.…”

Section: Discussionmentioning

confidence: 94%

Effects of oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders

Bisceglie¹,

Bertagna²,

Composto³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

Pretherapy sperm cryopreservation in young men is currently included in good clinical practice guidelines for cancer patients. The aim of this paper is to outline the effects of different oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders, based on an 8-year experience of the Cryopreservation Centre of a large public hospital. Two hundred and sixty-one patients with testicular neoplasia and 219 patients with lymphoproliferative disorders who underwent chemotherapy and/or radiotherapy and pretherapy semen cryopreservation were evaluated. Sperm and hormonal parameters (follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, inhibin B levels) were assessed prior to and 6, 12, 18, 24 and 36 months after the end of cancer treatment. At the time of sperm collection, baseline FSH level and sperm concentration were impaired to a greater extent in patients with malignant testicular neoplasias than in patients with lymphoproliferative disorders. Toxic effects on spermatogenesis were still evident at 6 and 12 months after the end of cancer therapies, while an improvement of seminal parameters was observed after 18 months. In conclusion, an overall increase in sperm concentration was recorded about 18 months after the end of cancer treatments in the majority of patients, even if it was not possible to predict the evolution of each single case 'a priori '. For this reason, pretherapy semen cryopreservation should be considered in all young cancer patients.

show abstract

Section: Discussionmentioning

confidence: 94%

Effects of oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders

Bisceglie¹,

Bertagna²,

Composto³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…33 Given that patients with fever nearly always had night sweats as well, it was not possible to determine which of the individual B-symptoms had the strongest impact. Another limitation of our study is that only patients with early stage disease were enrolled: two other studies 30,34 previously showed that advanced-stage disease has a greater negative effect than early-stage disease on semen quality.…”

Section: Discussionmentioning

confidence: 99%

Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials

Kaaij¹,

Heutte²,

Echten-Arends³

et al. 2009

Haematologica

View full text Add to dashboard Cite

BackgroundAlthough widely recommended, cryopreservation of sperm is sometimes not performed for patients with Hodgkin's lymphoma because of presumed poor sperm quality related to the disease. We investigated sperm quality and factors determining it in untreated patients with early stage Hodgkin's lymphoma. Design and MethodsOf 2362 males who participated in EORTC H6-H9 trials, 474 (20%) had data available. Sperm quality was defined according to World Health Organization guidelines. Determining factors were studied by logistic regression analysis. ResultsThe median sperm concentration was 40×10 6 /mL (range, 0-345×10 6 /mL) and the median motility 50% (range, 0-90%). Sperm quality was good (concentration ≥20×10 6 /mL and motility ≥50%), intermediate (concentration ≥5×10 6 /mL) and poor (concentration <5×10 6 /mL but >0) in 41%, 49% and 7% of patients, respectively. Three percent of the patients were azoospermic. No relation was found between sperm quality and age or clinical stage of the Hodgkin's lymphoma, but B-symptoms and elevated erythrocyte sedimentation rate predicted poor sperm quality. The odds ratios for the association of poor sperm quality with the variables examined were: presence of B-symptoms, 2.77 (95% CI, 1.50-5.12; p=0.001); erythrocyte sedimentation rate of 50 mm/h or greater, 2.35 (95% CI, 1. p=0.009); fever, 3.22 (95% CI, p=0.005), and night sweats, 3.78 (95% CI, 1.97-7.26; p<0.001). There was no relation between sperm quality and pre-treatment follicle stimulating hormone level. ConclusionsIn this large study of males with Hodgkin's lymphoma, 90% had good or intermediate sperm quality. Three percent were azoospermic. There was an association between sperm quality and the presence or absence of B-symptoms, in particular fever and night sweats. With modern fertilization techniques, in most patients with early-stage Hodgkin's lymphoma sperm quality before treatment is good enough for future fatherhood.Key words: Hodgkin's lymphoma, fertility, male, sperm quality, sperm. Citation: van der

show abstract

“…Чаще нарушения сперма-тогенеза наблюдаются при лимфоме Ходжкина (ЛХ), неходжкинской лимфоме (НХЛ), остром лимфобласт-ном лейкозе (ОЛЛ), опухолях яичка [9,10] и проявля-ются снижением показателей спермограммы [11][12][13]. По разным данным, инициальные нарушения сперма-тогенеза встречаются от 25 до 70 % при ЛХ и других опухолях [6,[14][15][16][17]. Неспецифическое влияние опухо-ли на сперматогенез происходит при длительном суб-фебрилитете, потере веса, значительной распростра-ненности опухолевого процесса или очага и других системных нарушениях [18][19][20].…”

Section: влияние опухолевого процесса на сперматогенезunclassified

“…Дмитрия Рогачева были направлены на криоконсервацию 30 человек, средний возраст кото-рых составил 16 (15)(16)(17) Работа над проблемой сохранения фертильности у юношей сопряжена с трудностями, которые условно можно разделить на несколько групп: связанные с информированием, клиническими, физиологиче-скими, юридическими, этическими и финансовыми ограничениями.…”

Section: (рис 2)unclassified

Prevention of male infertility in the treatment of tumors. Problems and solutions

Алексеевич¹,

Novichkova²,

Румянцев³

2016

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Testicular cancer and Hodgkin's disease: evaluation of semen quality

Abstract: Better semen quality was observed in patients with HD than in those with TC. The semen quality observed in our TC and HD groups seems better than previous results reported in the literature.

Cited by 68 publications

References 45 publications

Effects of oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders

Effects of oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders

Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials

Prevention of male infertility in the treatment of tumors. Problems and solutions

Contact Info

Product

Resources

About